Is There a Generic Zepbound? What the Law and the FDA Records Say (September 2026)

Quick answer

As of September 2026, there is no FDA-approved generic Zepbound and no FDA-approved generic tirzepatide. FDA's Drugs@FDA database lists exactly 2 approved tirzepatide applications, both new drug applications held by Eli Lilly and Company: Zepbound (NDA 217806, approved November 8, 2023) and Mounjaro (NDA 215866, approved May 13, 2022). No abbreviated new drug application, which is what a generic legally is, appears on the record. Anything sold online as "generic Zepbound" is therefore either a compounded preparation, which is not a generic, or an unapproved drug.

What does "generic" mean under US law?

In US drug law, "generic" has a narrow meaning. A generic drug is a product approved by FDA through an abbreviated new drug application (ANDA) under section 505(j) of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 355(j). The statute allows "any person" to file such an application, but the application must show that the proposed product matches an approved "listed drug" in active ingredient, route of administration, dosage form and strength, that it is bioequivalent to that listed drug, and that its labeling matches except for permitted differences.

FDA's own compounding Q&A draws the line in one sentence: a generic drug "is approved by FDA under 505(j) of the FD&C Act and meets all of the requirements of that section," while "a compounded drug is not approved by FDA."

So the test for "is there a generic Zepbound" is simple: is there an approved ANDA that references Zepbound as its listed drug? As of September 2026 the answer from FDA's records is no.

Why is there no generic Zepbound yet?

Two things stand between an approved brand and an approved generic: patents and regulatory exclusivity. FDA publishes both for each approved product in the Orange Book. For Zepbound, NDA 217806, product 001, the Orange Book patent page printed the following on September 19, 2026.

Zepbound patent expiration entries, with the date as printed:

• U.S. Patent 9,474,780, listed as claiming the drug substance and the drug product, expiring 05/13/2036
• U.S. Patents 11,357,820 and 12,453,756, listed as claiming the drug product, expiring 06/14/2039
• U.S. Patent 12,629,404, listed as claiming the drug product and with patent use codes, expiring 06/14/2039
• U.S. Patent 11,918,623, listed with a patent use code, expiring 06/14/2039
• U.S. Patents 12,343,382, 12,453,758 and 12,616,740, listed with patent use codes, expiring 07/22/2039

Exclusivity entries, with the expiration date as printed:

• NP, expiring 11/08/2026
• NCE, expiring 05/13/2027
• M-82, expiring 10/18/2027
• I-958, expiring 12/20/2027

Two caveats come from FDA itself. First, the Orange Book page carries a standing notice that users "should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner." Second, patent listings and exclusivity entries change over time as new patents are added, as litigation is decided, and as settlements are reached. The dates above are what the record printed on September 19, 2026, not a promise about when a generic will appear.

The reason the dates matter is procedural. An ANDA applicant must certify to each listed patent, and a certification that a patent is invalid or not infringed can trigger litigation and a statutory stay of approval. Even after the last listed date passes, FDA still has to review and approve the application. Exclusivity is separate from patents and runs on its own clock.

When will Zepbound go generic?

No one outside FDA and the applicants can answer that with a date, and the Orange Book does not try to. What the record supports saying is narrower: the earliest printed exclusivity entry for Zepbound expires in November 2026, the last printed patent entries expire in 2039, and every one of those dates can move. A listing that claims to sell a generic today is not describing an FDA-approved generic, because none exists on the record.

Is Mounjaro a generic for Zepbound? One molecule, two labels

Tirzepatide is sold under two brand names, Zepbound and Mounjaro, and the word "generic" also gets misused for Mounjaro. Both products contain tirzepatide; both prescribing information documents describe tirzepatide as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. What differs is the approved use on each label.

The Zepbound label states that it is indicated, in combination with a reduced-calorie diet and increased physical activity, "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition," and to treat moderate to severe obstructive sleep apnea in adults with obesity.

The Mounjaro label states that it is indicated "as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus," and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. Weight management is not among Mounjaro's approved indications. Whether either product is appropriate for a given person, and which one, is a decision for a licensed physician working from the label.

Neither product is a generic of the other. Each was approved under its own new drug application, and Drugs@FDA lists both as new drug applications from one sponsor. For background on how this class of medicine works, see what a GLP-1 medication is.

Is compounded tirzepatide a generic?

No. Compounded medications are not FDA-approved as final products. A compounded preparation is made by a pharmacy or an outsourcing facility for a patient under the conditions of section 503A or section 503B of the FD&C Act, and FDA's consumer page on unapproved GLP-1 drugs explains that the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed." A generic, by contrast, has gone through ANDA review and approval. The two are different legal categories, and a seller who calls a compounded product a "generic" is using the word in a way the law does not.

Federal law and FDA policy allow compounders to prepare copies of a drug while it is on FDA's drug shortage list under certain conditions, but section 503A otherwise bars compounding a product that is "essentially a copy of a commercially available drug product," with a narrow exception for a change that produces a significant difference for an identified individual patient, as determined by the prescribing practitioner. FDA announced on December 19, 2024 that the tirzepatide injection shortage was resolved, and its statement adds that "when a drug shortage is resolved, FDA generally considers the drug to be commercially available." The FDA drug shortages database still listed Tirzepatide Injection as resolved on September 19, 2026.

For how the two pharmacy types differ, see 503A versus 503B pharmacies, and for the safety questions a patient should raise, see is compounded tirzepatide safe.

Is there a lower-price route from the manufacturer?

The Zepbound prescribing information lists several presentations of the approved product: prefilled single-dose pens, single-dose vials, a multi-dose vial, and a single-patient-use KwikPen. All of them are injections; there is no approved tablet, and whether an oral tirzepatide exists covers the products sold under that name. Vials are the only Zepbound presentation listed on the federal TrumpRx site, which routes orders to the manufacturer's own LillyDirect channel.

As of September 2026, TrumpRx.gov lists Zepbound Vial at a lowest deal price of $299 per month against an original price of $1,087 per month, describes the figure as an out-of-pocket price, and states that Eli Lilly and Company manages all Zepbound Vial orders through LillyDirect. The listing states that eligibility is required and that terms and conditions apply, and that LillyDirect guides the buyer through eligibility confirmation. Prices on that page can change, so the figures above are a snapshot dated September 2026 and nothing more.

The label also directs prescribers to tell patients which presentation they will receive and to ensure they receive training for that presentation. For the pen-based presentation, see the Zepbound KwikPen, and for reading the label on any of them, see how to read a prescription label.

How can I check whether an online "generic Zepbound" offer is legal?

Because no FDA-approved generic exists, a "Zepbound generic" offer is itself a signal to slow down. FDA's page on unapproved GLP-1 drugs says that patients "should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy," and its BeSafeRx campaign exists to help people "recognize the signs of safe online pharmacies and the warning signs of websites that appear to be pharmacies but may be unsafe."

1. Find the dispensing pharmacy's name and state. A lawful listing names the pharmacy that will fill the order. If the site will not say which pharmacy dispenses, stop there.
2. Look the pharmacy up on its state board of pharmacy. Every state board runs a public license lookup. California's board, for example, states that information on its website "can be accepted as verification of a license." Confirm the license is active and that the pharmacy is licensed to ship into your state.
3. Confirm a prescription is required. FDA's guidance and the compounding statute both start from a valid prescription from a licensed practitioner. A site that sells tirzepatide with no prescription is not operating within either the approval system or the compounding exemptions.
4. Read what the listing says about approval. If it says the product is compounded, it is not a generic. Compounded medications are not FDA-approved as final products. If it says the product is "FDA-approved generic tirzepatide," compare that claim with Drugs@FDA, which lists no such product.
5. Ask which facility made it and under which section. A 503A pharmacy compounds for an individual patient on a prescription; a 503B outsourcing facility registers with FDA and, in FDA's words, is "primarily overseen by FDA and inspected by FDA according to a risk-based schedule." A seller should be able to say which applies.
6. Treat imported or "research use" vials as outside the system. FDA's unapproved GLP-1 page warns that illegally marketed products may be counterfeit or contain the wrong ingredient, too little, too much or none of the active ingredient, and urges consumers to buy only from state-licensed pharmacies.

These checks apply equally to semaglutide offers, covered in is compounded semaglutide FDA-approved.

Questions to ask a physician

A licensed physician makes the prescribing decision; useful questions help that decision rather than pre-empt it.

• Which tirzepatide product, if any, does my history support, and what does its label say it is approved for?
• If cost is the constraint, does the manufacturer's vial channel change the picture for me, and what training would I need for a vial?
• If a compounded product is being proposed, which pharmacy or outsourcing facility would prepare it, under which section of the law, and why is a compounded product appropriate for me specifically?
• What warnings on the label apply to me, and what would make you stop or change treatment? The label's warnings are summarized in Zepbound side effects.
• How would I report a problem with the product, and to whom?

If a generic tirzepatide is approved in the future, it will appear in Drugs@FDA and the Orange Book before it appears in any advertisement. Until then, the honest answer to "is there a generic for Zepbound" is no. Questions about how this site handles medical content are answered on the help page.

Compounded medications are not FDA-approved as final products. This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Regulatory records, patent listings and prices change; the dates and figures above reflect the sources as read on September 19, 2026.